Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018.
Hui ShaoMichael LaxyStephen R BenoitYiling J ChengEdward W GreggPing ZhangPublished in: Diabetes care (2021)
Average annual payments and OOP payment for noninsulin glucose-lowering drugs increased significantly from 2005 to 2018. The uptake of newer drug classes was the main driver.